# US 2021/0275460 A1 · Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275460 A1
- Document ID: US20210275460A1
- Status: Published application
- Kind: A1
- Application number: 17/328,911
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2019-04-12
- Assignees: Sopharma Ad
- Applicants: Sopharma Ad
- Inventors: Angel Aleksiev Aleksiev; Veselin Evgeniev Daskalov
- Web page: https://patentgrep.com/patent/US20210275460A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 25/32: Alcohol-abuse
- A61K 9/2009: {Inorganic compounds}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is related to an oral pharmaceutical composition that contains a cholinergic agent, a natural plant alkaloid in particular, selected from the group of lobeline, anabasine, cytisine, galantamine or their acceptable salts, in the form of tablets and capsules. The excipients of the developed oral composition include cellulose powder, calcium sulphate, silica colloidal and magnesium stearate, the total content of cellulose powder and calcium sulphate dihydrate being from 64.5 to 97.5% of the mass of the dosage form and at least 90% of the alkaloid particles being ≤100 μm. The oral composition contains also at least one biologically active amino acid selected from: L-carnitine, tryptophan or a combination of them. The oral composition according to this invention achieves uniform distribution of the active substance in the composition, as well as stability of the composition due to the included excipients selected so as to react to a minimum with the alkaloid to form the qualitative and quantitative related substances admissible for the pharmaceutical composition. The composition according to this invention is applicable in the treatment of dependency and addiction to nicotine, tobacco products and alcohol.

## Claims

### Claim 1

An oral pharmaceutical composition comprising, a therapeutically effective amount of a natural plant alkaloid or acceptable salt thereof, at least one pharmaceutically acceptable excipient, and optionally at least one biologically active amino acid, wherein: (1) the natural plant alkaloid or acceptable salt thereof comprises 1.5 mg to 3.0 mg cytisine or acceptable salt thereof, 5 mg to 20 mg galantamine or acceptable salt thereof, 1.5 to 2.0 mg lobeline or acceptable salt thereof, or 1.5 mg to 3.0 mg anabasine or acceptable salt thereof, (2) the at least one pharmaceutically acceptable excipient comprises cellulose powder, calcium sulphate, silica colloidal and magnesium stearate, with the cellulose powder and the calcium sulphate representing 64.5% to 97.5% by weight of the pharmaceutical composition, and wherein the natural plant alkaloid or acceptable salt thereof is composed of particles, at least 90% of which are of not more than 100 μm in diameter.

### Claim 2 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 5.0% to 92.5% by weight cellulose powder, 5.0% to 92.5% by weight calcium sulphate, 0.5% to 3.0% by weight silica colloidal, and 0.5% to 3.0% by weight magnesium stearate.

### Claim 3 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of tablets or hard capsules.

### Claim 4 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the at least one biologically active amino acid comprises 0.2 mg to 0.4 mg L-carnitine, 5 mg to 55 mg tryptophan, or a combination thereof.

### Claim 5 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the pharmaceutical composition is used for treatment of dependency or addiction to nicotine, tobacco products, or alcohol.

### Claim 6 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the pharmaceutical composition does not contain lactose.
